Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients

Clinical and Experimental Nephrology

Volumn 14, Issue 6, 2010, Pages 589-597

  Shigematsu, Takashi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Hemodialysis; Hyperphosphatemia; Lanthanum carbonate; Phosphate binder

Indexed keywords

CALCIUM; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

ADULT; ARTICLE; BONE TURNOVER; BREAST CANCER; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROCARDIOGRAM; FEMALE; GASTROINTESTINAL DISEASE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IRON DEFICIENCY ANEMIA; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; REFLUX ESOPHAGITIS; SIDE EFFECT; STOMACH DISCOMFORT; UNSTABLE ANGINA PECTORIS; UPPER ABDOMINAL PAIN; VITAL SIGN; VOMITING;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LANTHANUM; MALE; MIDDLE AGED; PHOSPHATES; RENAL DIALYSIS; TREATMENT OUTCOME; VITAMIN D;

EID: 78650949116     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-010-0339-3     Document Type: Article

References (24)

1. GA Block TE Hulbert-Shearon NW Levin FK Port 1998 Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study Am J Kidney Dis 31 607 617 1:STN:280:DyaK1c7ovFKlsw%3D%3D 10.1053/ajkd.1998.v31.pm9531176 9531176
2. WY Qunibi 2004 Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD) Kidney Int Suppl 90 S8 S12 1:CAS:528: DC%2BD2cXnvVCrurw%3D 10.1111/j.1523-1755.2004.09004.x 15296501
3. S Mathew KS Tustison T Sugatani LR Chaudhary L Rifas KA Hruska 2008 The mechanism of phosphorus as a cardiovascular risk factor in CKD J Am Soc Nephrol 19 1092 1105 1:CAS:528:DC%2BD1cXns1yitLY%3D 10.1681/ASN.2007070760 18417722
4. AJ Hutchison 2009 Oral phosphate binders Kidney Int 75 906 914 1:CAS:528:DC%2BD1MXks1SjsL4%3D 10.1038/ki.2009.60 19279554
5. VP Persy GJ Behets AR Bervoets ME De Broe PC D'Haese 2006 Lanthanum: a safe phosphate binder Semin Dial 19 195 199 10.1111/j.1525-139X.2006.00169.x 16689967 (Pubitemid 43742655)
6. IA Mohammed AJ Hutchison 2008 Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate Ther Clin Risk Manag 4 887 893 1:CAS:528:DC%2BD1cXhsFers7%2FO 19209270
7. MS Joy WF Finn 2003 Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia Am J Kidney Dis 42 96 107 1:CAS:528:DC%2BD3sXmtVajtL0%3D 10.1016/S0272-6386(03)00554-7 12830461 (Pubitemid 36807658)
8. AJ Hutchison M Speake F Al-Baaj 2004 Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate Nephrol Dial Transplant 19 1902 1906 1:CAS:528:DC%2BD2cXltVWksLs%3D 10.1093/ndt/gfh282 15199195 (Pubitemid 38961407)
9. WF Finn MS Joy G Hladik 2004 Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis Clin Nephrol 62 193 201 1:CAS:528:DC%2BD2cXotVGqt7c%3D 15481851
10. SS Chiang JB Chen WC Yang 2005 Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease Clin Nephrol 63 461 470 1:CAS:528:DC%2BD2MXlslaks7Y%3D 15960148
11. F Al-Baaj M Speake AJ Hutchison 2005 Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study Nephrol Dial Transplant 20 775 782 1:CAS:528:DC%2BD2MXisVGqt7k%3D 10.1093/ndt/gfh693 15703206 (Pubitemid 40520656)
12. AJ Hutchison B Maes J Vanwalleghem G Asmus E Mohamed R Schmieder, et al. 2005 Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate Nephron Clin Pract 100 c8 c19 1:CAS:528:DC%2BD2MXjsFyrsbY%3D 10.1159/000084653 15809508 (Pubitemid 40674602)
13. PC D'Haese GB Spasovski A Sikole A Hutchison TJ Freemont S Sulkova, et al. 2003 A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients Kidney Int Suppl 85 73 78 10.1046/j.1523-1755.63.s85.18.x
14. WF Finn MS Joy 2005 A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis Curr Med Res Opin 21 657 664 1:CAS:528: DC%2BD2MXlslakt70%3D 10.1185/030079905X41453 15969865 (Pubitemid 40695287)
15. AJ Freemont JA Hoyland J Denton 2005 The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease Clin Nephrol 64 428 437 1:CAS:528:DC%2BD2MXhtlCisLzN 16370155
16. GB Spasovski A Sikole S Gelev J Masin-Spasovska T Freemont I Webster, et al. 2006 Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up Nephrol Dial Transplant 21 2217 2224 1:CAS:528: DC%2BD28Xotl2ktb0%3D 10.1093/ndt/gfl146 16595583 (Pubitemid 44295048)
17. WF Finn 2006 Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients Clin Nephrol 65 191 202 1:CAS:528:DC%2BD28Xht1eht77N 16550750
18. AJ Hutchison B Maes J Vanwalleghem G Asmus E Mohamed R Schmieder, et al. 2006 Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study Nephron Clin Pract 102 c61 c71 1:CAS:528:DC%2BD28Xit12rtQ%3D%3D 10.1159/000088932 16224198 (Pubitemid 43087563)
19. AJ Hutchison ME Barnett R Krause JT Kwan GA Siami 2008 SPD405-309 Lanthanum study group. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment Nephron Clin Pract 110 c15 c23 1:CAS:528:DC%2BD1cXhtFCis7vM 10.1159/000149239 18667837
20. T Shigematsu 2008 Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis Ther Apher Dial 12 55 61 1:CAS:528:DC%2BD1cXktVGqu7k%3D 10.1111/j.1744-9987.2007.00541.x 18257813 (Pubitemid 351197453)
21. T Shigematsu Lanthanum Carbonate Group 2008 Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia Clin Nephrol 70 404 410 1:CAS:528:DC%2BD1MXks1ahuw%3D%3D 19000540
22. T Shigematsu 2010 One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis Ther Apher Dial 14 1 12 19 1:CAS:528:DC%2BC3cXkvVeju7g%3D 10.1111/j.1744-9987.2009.00697.x 20438515
23. DA Goodkin EW Young K Kurokawa KG Prütz NW Levin 2004 Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects Am J Kidney Dis 44 Suppl 2 16 21 10.1016/S0272-6386(04)01100-X 15486869
24. M Pennick K Dennis SJ Damment 2006 Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate J Clin Pharmacol 46 738 746 1:CAS:528:DC%2BD28XntlWgsb0%3D 10.1177/0091270006289846 16809799 (Pubitemid 43882797)